Skip to main content
. 2020 Sep 1;9(9):2013. doi: 10.3390/cells9092013

Figure 6.

Figure 6

Synergistic anticancer effect of irinotecan treatment with OxPhos inhibitors. (A) Representative images showing immunohistochemical staining with anti-Ki-67 as a measure of tumor proliferative activity in the SNU-638 and A375 xenograft models used in Figure 5. (B) Representative images showing immunohistochemical staining with anti-NDUFB8 (mitochondrial complex I) as a measure of OxPhos activity in tumors from SNU-638 and A375 xenograft control and anticancer drug treatment groups. P values were analyzed by unpaired two-tailed Student’s t test. *, p < 0.05; **, p < 0.01.